The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | An update on Alliance A061202: addition of ixazomib to pomalidomide-dexamethasone in R/R myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on the Alliance A061202 study (NCT02004275), which is a randomized Phase II study evaluating the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma refractory to lenalidomide. When ixazomib was administered early, there was a striking progression-free survival (PFS) benefit of 21 months for the triplet drug combination versus 7.5 months for the control group. When ixazomib was added later, the PFS gain was ~6 months, suggesting that ixazomib provides a greater benefit when administered early. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
